Drug intelligence / Profile preview

amoxicillin + tetracycline + bismuth + tegoprazan

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of amoxicillin (antibiotic), tetracycline (antibiotic), bismuth (antimicrobial agent), and tegoprazan (potassium-competitive acid blocker). This combination is designed for Helicobacter pylori eradication. Tegoprazan is a novel P-CAB that provides rapid, potent, and sustained night-time acid suppression compared to other acid suppressants. The bismuth component helps overcome antibiotic resistance, while amoxicillin and tetracycline provide antimicrobial activity against H. pylori.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)Bacterial Ribosome

Beyond the preview

Go deeper on amoxicillin + tetracycline + bismuth + tegoprazan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + tetracycline + bismuth + tegoprazan.

Explore the full profile